TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Dec 16, 2022 11:00 JST
Source:
Olympus
Olympus Named to Dow Jones Sustainability World Index for Two Consecutive Years
TOKYO, Dec 16, 2022 - (JCN Newswire) - Olympus Corporation (Olympus), a global medtech company committed to making people's lives healthier, safer and more fulfilling, announced that it has been selected for inclusion in the 2022 Dow Jones Sustainability World Index (DJSI World) and the 2022 Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), both among the most globally recognized corporate sustainability indices. Olympus has been named to the DJSI World for two consecutive years and DJSI Asia Pacific for four.
The Dow Jones Sustainability Indices (DJSI) are corporate sustainability evaluation indices for environmental, social, and governance (ESG) investment. Jointly developed by S&P Dow Jones Indices and RobecoSAM, the DJSI track the financial performances of leading companies according to ESG criteria. These indices are updated annually to include companies with excellent corporate sustainability practices.
In 2022, 332 companies were selected as DJSI World members from approximately 3,500 companies worldwide in 61 industry sectors, and 156 companies were selected as DJSI Asia Pacific members from approximately 600 companies assessed in the region. Olympus is one of only 8 out of 64 companies to have been included in the DJSI World Health Care Equipment & Supplies sector. The company's scores on Access to Healthcare, Talent Attraction & Retention, Tax Strategy, Environmental Policy & Management Systems were of particular note, being not only highly rated, but having also been improved over last year's scores. In addition to the DJSI World and Asia Pacific, Olympus was also named to the FTSE4Good Index Series and FTSE Blossom Japan Index.
Stefan Kaufmann; Director, Executive Officer, and Chief Administrative Officer of Olympus, stated: "It is a great honor for Olympus to again be selected for the DJSI World and Asia Pacific. In order to realize Our Purpose of Making people's lives healthier, safer and more fulfilling, we have taken various initiatives to contribute to society, positioning ESG as one of the most important strategic pillars in our Corporate Strategy. We are proud to be included in the DJSI World and Asia Pacific for consecutive years as evidence of our continuous evolution as well as our high reputation in ESG from stakeholders. We will further accelerate our efforts to realize a sustainable society."
Based on Our Purpose, Olympus believes that the sustainability of a company will be recognized primarily by meeting the demands and expectations of society and fulfilling responsibilities through dialogue with all stakeholders. The company will continue to contribute to creating a sustainable society by actively engaging in activities that incorporate ESG perspectives to fulfill its corporate social responsibilities on a global scale.
For more information on Olympus' ESG initiatives, please refer to its Integrated Report 2022[1] and the Sustainability page on its website[2].
[1]
https://www.olympus-global.com/ir/data/integratedreport/2022.html?page=ir
[2]
https://www.olympus-global.com/csr/
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. Olympus is headquartered in Tokyo, Japan, with more than 30,000 employees worldwide in nearly 40 countries and regions. For more information, visit www.olympus-global.com and follow our global Twitter account: @Olympus_Corp (
https://twitter.com/olympus_corp
).
Media contact:
Mieko Yamada
Global-Public_Relations@olympus.com
Olympus Corp [TYO: 7733] [ADR: OCPNY] [GDR: OLYS]
https://www.olympus-global.com
Source: Olympus
Sectors: Environment, ESG, BioTech, Healthcare & Pharm, Funds & Equities, MedTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
November 19 2024 14:30 JST
Olympus Launches VISERA S, a New Imaging Platform
September 30 2024 14:00 JST
Olympus Launches New 4K Camera Head for Urological Endoscopy
September 20 2024 14:00 JST
Olympus Enhances Innovation Capabilities by Expanding R&D to Hyderabad, India
June 12 2024 10:00 JST
NTT and Olympus Begin World's First Joint Demonstration Experiment of Cloud Endoscopy System
March 27 2024 14:00 JST
Olympus Closes the Acquisition of Korean Gastrointestinal Stent Company, Taewoong Medical Co., Ltd
January 24 2024 14:00 JST
Olympus Named to Dow Jones Sustainability World Index for Three Consecutive Years
December 11 2023 10:00 JST
Vesica AI Selected as Winner of Inaugural Olympus Asia Pacific Innovation Program
December 07 2023 10:00 JST
Olympus's Net-Zero Targets Approved by SBTi
November 30 2023 10:00 JST
Olympus Names Dr. John de Csepel as Chief Medical Officer
October 06 2023 20:00 JST
More Press release >>
Latest Press Release
Kaplan Fox & Kilsheimer LLP Alerts Investors to a Securities Class Action Against Humacyte, Inc. (HUMA) - Deadline is January 17, 2025
Nov 22, 2024 11:00 JST
NaaS Q3 2024 Recap: Strategic Shifts and Tech Innovations for Growth
Nov 21, 2024 22:59 JST
Honda Unveils Demonstration Production Line for All-Solid-State Batteries Located in Sakura City, Tochigi Prefecture, Japan
Nov 21, 2024 15:35 JST
Deadline to Lead in Securities Fraud Lawsuit Against Humacyte, Inc. (HUMA) is January 17, 2025 - Contact Kaplan Fox & Kilsheimer LLP
Nov 21, 2024 09:00 JST
ALL Study Groups Using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study
Nov 20, 2024 23:05 JST
Start of Demonstration Test of Two-Phase Direct-to-Chip Cooling in the Air-Cooled Data Center
Nov 20, 2024 15:30 JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 11:51 JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 20, 2024 10:24 JST
Kingsoft Announces 2024 Third Quarter Results
Nov 19, 2024 18:54 JST
NTT and Olympus Joint Demonstration Shows IOWN APN's Low-latency Capability Can Be Used for Real-time Diagnosis and Treatment on a Remote Server to Realize World's First Cloud Endoscopy System
Nov 19, 2024 15:30 JST
Supercomputer Fugaku retains first place worldwide in HPCG and Graph500 rankings
Nov 19, 2024 09:02 JST
CleverTap Recognized as a Strong Performer in Cross-Channel Marketing Hubs, Q4 2024 Report
Nov 18, 2024 23:30 JST
World's First Successful Trial of Quantum Tokens Created Using Quantum Technology
Nov 18, 2024 17:29 JST
Fujitsu and SAP Fioneer enter partnership to accelerate digital transformation in the insurance industry and deliver services that contribute to customers' sustainable business
Nov 18, 2024 12:31 JST
Expanding Possibilities with the Liquid Hydrogen-Powered GR Corolla in the Season Final Round
Nov 18, 2024 09:25 JST
COP29: Indonesian Special Envoy Hashim Djojohadikusumo Announces EUR 1,2 Billion Green Funding
Nov 16, 2024 18:00 JST
Mitsubishi Shipbuilding Holds Christening and Launch Ceremony of LNG-Powered Roll-on/Roll-off Ship TRANS HARMONY EMERALD in Shimonoseki
Nov 15, 2024 18:58 JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 17:33 JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 15, 2024 14:31 JST
Resorttrust Group and Mitsubishi Corporation Launch Joint Study in Medical Tourism
Nov 15, 2024 12:32 JST
More Latest Release >>